SCHEMBL406586

SCHEMBL406586

BrNNc1ccccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10405315 0.85 MEN1 (0.61)
Hydrochloric Acid SCHEMBL8742967 0.82 MEN1 (0.58)
SCHEMBL2227737 0.81
SCHEMBL250513 0.80
SCHEMBL7534423 0.76
SCHEMBL27370986 0.76
SCHEMBL27948307 0.76
SCHEMBL7018736 0.76
SCHEMBL24134532 0.75
SCHEMBL19418969 0.74 ALDH1A1 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202840-B2 Compounds for the treatment or alleviation of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2025-01-21 US disclosed
EP-3802528-B1 NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC IMMUNE SA (CH) 2022-07-06 EP disclosed
US-20210214371-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2021-07-15 US disclosed
EP-3802528-A1 NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC Immune SA (CH) 2021-04-14 EP disclosed
WO-2019233745-A1 NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC IMMUNE SA (CH) 2019-12-12 WO disclosed
CN-106061963-B Heterocyclic modulators of lipid synthesis and combinations thereof 3-V生物科学股份有限公司 2019-10-22 CN disclosed
CN-110214136-A Pyrazole derivatives as MALT1 inhibitor 詹森药业有限公司 2019-09-06 CN disclosed
CN-110088101-A A kind of nitrogen-containing hetero cyclics, preparation method, pharmaceutical composition and application 罗欣药业(上海)有限公司 2019-08-02 CN disclosed
CN-109970708-A Cannibinoid receptor modulators 艾尼纳制药公司 2019-07-05 CN disclosed
EP-2558446-B1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2019-06-12 EP disclosed
US-20110280808-A1 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins AC IMMUNE, S.A. (CH) 2011-11-17 US disclosed
WO-2011128455-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE S.A. (CH) 2011-10-20 WO disclosed
US-7700593-B2 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2010-04-20 US disclosed
WO-2009126624-A1 TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-15 WO disclosed
EP-2086973-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF Amgen Inc., (US) 2009-08-12 EP disclosed
US-20080161303-A1 Imidazo- and triazolo-pyridine compounds and methods of use thereof AMGEN INC. (US) 2008-07-03 US disclosed
CN-100387594-C Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO INC (US) 2008-05-14 CN disclosed
WO-2008045393-A2 IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF AMGEN INC. (US) 2008-04-17 WO disclosed
CN-1795184-A Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO INC (US) 2006-06-28 CN disclosed
CN-1067892-A The preparation method of new pyrrolo-[2,3-b] pyridine derivate ASTRA AB (SE) 1993-01-13 CN disclosed